Law360, New York (December 9, 2013, 6:47 PM EST) -- Resolving long-running multidistrict litigation in New York, Merck & Co. Inc. agreed Monday to pay $27.7 million to settle hundreds of lawsuits claiming its bone drug Fosamax caused a condition known as osteonecrosis of the jaw.
The agreement includes the claims of about 1,200 plaintiffs in federal and state court, Merck said. It comes after U.S. District Judge John Keenan ordered the parties to transfer 200 cases per month out of the multidistrict litigation and into their home courts, though no such transfer has yet occurred.
Since the litigation began in 2005, seven bellwether trials have gone to verdict, with Merck...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!